These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6965439)

  • 21. A matched-pair study of the leukocyte elastase-like activity in normal persons and in emphysematous patients with and without alpha 1-antitrypsin deficiency.
    Kramps JA; Bakker W; Dijkman JH
    Am Rev Respir Dis; 1980 Feb; 121(2):253-61. PubMed ID: 6965829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current views on the pathogenesis and treatment of pulmonary emphysema and chronic bronchitis].
    Fal A
    Wiad Lek; 1992 Mar; 45(5-6):233-9. PubMed ID: 1455869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.
    Hubbard RC; Crystal RG
    Am J Med; 1988 Jun; 84(6A):52-62. PubMed ID: 3289387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.
    Hubbard RC; McElvaney NG; Sellers SE; Healy JT; Czerski DB; Crystal RG
    J Clin Invest; 1989 Oct; 84(4):1349-54. PubMed ID: 2794066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cigarette smoking and the etiopathogenesis of pulmonary emphysema].
    Górecka D
    Pneumonol Pol; 1984 Jul; 52(7):353-7. PubMed ID: 6387638
    [No Abstract]   [Full Text] [Related]  

  • 26. [Possibilities of the prevention and treatment of pulmonary emphysema in the light of the "proteolytic" theory of its pathogenesis].
    Nowak D
    Pneumonol Pol; 1985 Oct; 53(10):492-6. PubMed ID: 3912732
    [No Abstract]   [Full Text] [Related]  

  • 27. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
    Carter RI; Mumford RA; Treonze KM; Finke PE; Davies P; Si Q; Humes JL; Dirksen A; Piitulainen E; Ahmad A; Stockley RA
    Thorax; 2011 Aug; 66(8):686-91. PubMed ID: 21617168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha1-antitrypsin deficiency (second of two parts).
    Morse JO
    N Engl J Med; 1978 Nov; 299(20):1099-105. PubMed ID: 360065
    [No Abstract]   [Full Text] [Related]  

  • 29. The elastase-antielastase hypothesis of the pathogenesis of emphysema.
    Stone PJ
    Clin Chest Med; 1983 Sep; 4(3):405-12. PubMed ID: 6196148
    [No Abstract]   [Full Text] [Related]  

  • 30. On the influence of the substrate (elastin) in elastase-alpha 1 antitrypsin interactions.
    Hornebeck W; Soleilhac JM; Velebny V; Robert L
    Pathol Biol (Paris); 1985 Apr; 33(4):281-5. PubMed ID: 3892459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional assessment of genetic variants of alpha 1-antitrypsin.
    Billingsley GD; Cox DW
    Hum Genet; 1982; 61(2):118-22. PubMed ID: 6182087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune activation in α1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm.
    Baraldo S; Turato G; Lunardi F; Bazzan E; Schiavon M; Ferrarotti I; Molena B; Cazzuffi R; Damin M; Balestro E; Luisetti M; Rea F; Calabrese F; Cosio MG; Saetta M
    Am J Respir Crit Care Med; 2015 Feb; 191(4):402-9. PubMed ID: 25412116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic elastase inhibitors: prospects for use in the treatment of emphysema.
    Powers JC
    Am Rev Respir Dis; 1983 Feb; 127(2):S54-8. PubMed ID: 6600895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy.
    Wewers MD; Casolaro MA; Crystal RG
    Am Rev Respir Dis; 1987 Mar; 135(3):539-43. PubMed ID: 3493719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New possibilities in the treatment of pulmonary emphysema based on the knowledge of the pathogenetic mechanisms of this disease].
    Krasucka-Kluźniak A
    Pneumonol Pol; 1983 Oct; 51(10):531-6. PubMed ID: 6361700
    [No Abstract]   [Full Text] [Related]  

  • 36. [Substitution therapy with alpha-1-Pi in patients with alpha-1-Pi deficiency and progressive pulmonary edema].
    Konietzko N; Becker M; Schmidt EW; Rasche B; Ulmer WT; Ferlinz R; Lorenz J
    Dtsch Med Wochenschr; 1988 Mar; 113(10):369-73. PubMed ID: 3280283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A perspective on antitrypsin deficiency.
    Pierce JA; Dew TA
    South Med J; 1974 Oct; 67(10):1140-3. PubMed ID: 4137511
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin.
    Hubbard RC; Brantly ML; Sellers SE; Mitchell ME; Crystal RG
    Ann Intern Med; 1989 Aug; 111(3):206-12. PubMed ID: 2787611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Trypsin and pancreatic elastase-inhibitory capacity of serum and bronchoalveolar lavage fluid of smokers, ex-smokers and nonsmokers].
    Ebert W; Trefz G; Heck B; Schulz V
    Pneumologie; 1990 Feb; 44 Suppl 1():267-8. PubMed ID: 2367387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum protease inhibitory capacity. (Recent knowledge on alpha 1-antitrypsin deficiency).
    Massi G; Bruscalupi G; Auconi P
    Ric Clin Lab; 1982; 12(3):449-58. PubMed ID: 6291123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.